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Introduction: Hypercholesterolaemia is estimated to
cause 2.6 million deaths annually and one-third of
the cases of ischaemic heart disease. In Argentina,
the prevalence of hypercholesterolaemia increased
between 2005 and 2013 from 27.9% to 29.8%. Only
one out of four subjects with a self-reported
diagnosis of coronary heart disease is taking statins.
Since 2014, statins (simvastatin 20 mg) are part of
the package of drugs provided free-of-charge for
patients according to cardiovascular disease (CVD)
risk stratification. The goal of this study is to test
whether a complex intervention targeting physicians
and pharmacist assistants improves treatment and
control of hypercholesterolaemia among patients
with moderate-to-high cardiovascular risk in
Argentina.
Methods and analysis: This is a cluster trial of
350 patients from 10 public primary care centres in
Argentina to be randomised to either the intervention
or usual care. The study is designed to have 90%
statistical power to detect a 0.7 mmol/L reduction in
low-density lipoproteins cholesterol from baseline to
12 months. The physician education programme
consists of a 2-day initial intensive training and
certification workshop followed by educational
outreach visits (EOVs) conducted at 3, 6 and
9 months from the outset of the study. An on-site
training to pharmacist assistants during the first EOV
is performed at each intervention clinic. In addition,
two intervention support tools are used: an app
installed in physician’s smartphones to serve as a
decision aid to improve prescription of statins
according to patient’s CVD risk and a web-based
platform tailored to send individualised SMS
messages to patients.
Ethics and dissemination: Ethical approval was
obtained from an independent ethics committee.
Results of this study will be presented to the
Ministry of Health of Argentina for potential
dissemination and scale-up of the intervention
programme to the entire national public primary care
network in Argentina.
Trial registration number: NCT02380911.
HYPERCHOLESTEROLAEMIA: A MAJOR
GLOBAL PUBLIC HEALTH CHALLENGE
Hypercholesterolaemia, a condition that
accounts for a significant disease burden in
the developed and developing world, is esti-
mated to cause 2.6 million deaths annually
Strengths and limitations of this study
▪ There is scarce information about the effective-
ness of educational interventions targeted to
primary care physicians to improve primary pre-
vention of cardiovascular diseases in low- and
middle-income countries (LMIC), particularly in
low-resource settings.
▪ Cluster randomised clinical trials are an adequate
and powerful tool to evaluate educational inter-
ventions to change clinical practice.
▪ This implementation research study is highly
integrated into the health services provided by
the public health system in Argentina, which
allows for potential scalability of findings.
▪ As most of complex interventions based on mul-
tiple components, the whole is more than the
sum of the parts for what it is difficult to disen-
tangle the individual effect of each single compo-
nent. However, measurement of process
measures can help understand the change trig-
gered by the intervention or the lack thereof.
▪ If effective, this intervention should be replicated
at a larger scale and with longer follow-up to
assess sustainability.
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(4.5% of all deaths) and one-third of the cases of ischae-
mic heart disease.1 Globally, mean total cholesterol
levels changed little between 1980 and 2008, falling by
<0.1 mmol/L per decade for men and women. In 2008,
the global prevalence of elevated total cholesterol
among adults was 39% (37% for males and 40% for
females).2 Observational studies show that there is a con-
tinuous positive relationship between coronary heart
disease (CHD) and blood cholesterol concentrations.3
The Cholesterol Treatment Trialists’ (CTT)
Collaboration reported a meta-analysis4 of individual
data from 90 000 individuals in 14 randomised trials of
statin therapy versus control. Statin regimens resulted in
a mean difference of about 1.0 mmol/L in low-density
lipoprotein cholesterol (LDL-C) and a proportional
reduction of 20% in major vascular events (defined as
coronary death, non-fatal myocardial infarction, coron-
ary revascularisation or stroke). A recent meta-analysis
showed that trials comparing less intensive versus more
intensive statin regimens produced further reductions in
major vascular events.5–8
Although higher serum lipids level seems to be an
almost inevitable consequence of economic develop-
ment, urbanisation, westernisation and nutritional transi-
tion, these determinants can be offset through healthier
diets and pharmacological interventions. Consequently,
statins and other lipid-lowering drugs are increasingly
used in high-income countries.9 10 In low-income and
middle-income countries, however, coverage of screen-
ing and treatment is still very low.11–16
In Argentina, the National Risk Factor Surveys con-
ducted by the Ministry of Health indicate that between
2005 and 201317 self-reported prevalence of hyperchol-
esterolaemia rose from 27.9% to 29.8%. Of these, 54.8%
received some treatment, and only 56.3% of patients
treated were prescribed with lipid-lowering drugs (the
rate of those receiving treatment was <20% among unin-
sured subjects, including subjects with >3 risk factors).18
Recent baseline results from the CESCAS I Study—a
population-based prospective cohort study for the detec-
tion and follow-up of cardiovascular disease (CVD) and
risk factors in 7600 adults from four cities in Argentina,
Chile and Uruguay19 20 found that the prevalence of
hypercholesterolaemia in Argentina was 23.1% in men,
and 25.6% in women. According to the Framingham
heart study risk equation, the prevalence of non-optimal
LDL-C was 28.0%. On the other hand, the percentage
of subjects with hypercholesterolaemia who were aware
of their condition was 37.3% (95% CI 32.8 to 41.9), and
the percentage of aware patients under pharmacological
treatment was dismally low: only 11.1%. Furthermore,
only one in every four subjects with a self-reported diag-
nosis of CHD is taking statins, and most of those with
CHD who are on statins have suboptimal LDL-C levels
(Rubinstein et al. Personal communication. Data not yet
published). This is especially relevant because hyper-
cholesterolaemia accounts for 25% of the burden of
CHD in Argentina, as shown in another study.21
Use of evidence-based clinical practice guidelines (CPG)
to improve effectiveness and quality of treatment for
patients with dyslipidaemia
As CHD is highly prevalent and lipid-lowering drugs, par-
ticularly statins, are among the most frequently prescribed
drugs, lipid treatment guidelines have important implica-
tions for the health of the population and for the use of
healthcare resources.22 The International Atherosclerotic
Society (IAS) has recently issued a CPG for the manage-
ment of suboptimal LDL-C. It recommends statins as first-
line therapy, choosing the type of statin based on availabil-
ity and costs and adjusting the dose according to patient’s
CVD risk.23 More recently, the 2013 American College of
Cardiology and the American Heart Association (ACC/
AHA) panels updated their blood cholesterol guidelines.
They recommend the prescription of high-intensity statin
therapy (lowering LDL–C ≥50%) or moderate-intensity
therapy (lowering LDL–C by ∼ 30% to <50%), based on
the presence of prior CVD, LDL-C levels, type 2 diabetes,
age and the estimated 10-year risk of CVD according to
the risk estimates of pooled cohort equation.5 Owing to a
lack of evidence from randomised controlled trials (RCTs)
regarding the efficacy of titrating statins to reduce CVD,
guidelines no longer recommend this treatment to meet
specific LDL-C or non-high-density lipoprotein cholesterol
(HDL-C) goals.5 However, the publication of a CPG does
not ensure its application in clinical practice and, there-
fore, it is necessary to design effective implementation
plans specially tailored to the organisational context tar-
geted by the CPG.
Interventions to improve CPG implementation
Despite the availability of evidence-based practice guide-
lines, multiple barriers hinder the appropriate manage-
ment of hypercholesterolaemia in primary care settings.
These barriers include organisational hurdles within
primary care clinics; confusing and conflicting guide-
lines from external sources; errors and omissions by
primary care doctors; communication problems at the
interface between secondary and primary care,24 mul-
tiple competing demands on physicians’ time and lack
of reimbursement for preventive counselling.25 In add-
ition to this, there are other barriers related to (1) the
healthcare system (eg, lack of access, cost of medications
and poor insurance coverage); (2) healthcare providers
(eg, lack of adherence to guidelines, willingness to
accept elevated high cholesterol and failure to prioritise
this issue among multiple chronic medical issues) and
(3) patients (eg, reluctance to take medication).24
The interventions that have been effective in dealing
with barriers related to clinical practice include multifa-
ceted educational outreach visits (EOVs),26 27 audits and
feedback.27 28 EOVs have the potential to change health
professional practice, particularly physicians’ prescribing
patterns. The term EOV or ‘academic detailing’ is used
to describe a personal visit by a trained person to health
professionals in their own settings. A recent systematic
review on interventions to improve adherence to
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cardiovascular disease clinical guidelines showed a
global positive impact in intervention group compared
with usual care.27 The key principles of this approach
include surveys of practitioners to determine barriers for
appropriate practice and the subsequent development
of an intervention tailored to address those barriers
using simple messages; contacting practitioners with low
compliance and delivering the intervention through
respectable persons. Interventions often include feed-
back on existing practices.29 EOVs alone or combined
with other interventions have been effective in improv-
ing practice in the majority of circumstances: studies
with dichotomous health professional outcomes (eg,
proportion of patients treated in accordance with the
guideline) showed a 5.6% improvement, while studies
with continuous outcomes (eg, mean number of pre-
scriptions) showed at least 20% improvement.26 A recent
Cochrane review indicates that patient re-enforcement
and reminders seem to be the most promising interven-
tions to increase adherence to lipid-lowering drugs.
Other interventions associated with increased adherence
were simplification of the drug regimen and patient
information and education.30
Most of the interventions targeted to change provi-
der’s behaviours are usually defined as ‘complex inter-
ventions’. Complex interventions are described as
interventions that contain several interacting compo-
nents or ingredients and also other characteristics such
as a number and difficulty of behaviours required by
those delivering or receiving the intervention, distinct
groups or organisational levels targeted by the interven-
tion, a number and variability of outcomes and a bigger
latitude in the flexibility or tailoring of the intervention
that is permitted.31 In order to avoid that these complex
interventions become ‘black boxes’, it is critical that
process measures, in addition to outcomes, be planned
to be assessed along with the study.32
Throughout the implementation of this study, we will
consider the conceptual framework for evaluation of
implementation fidelity proposed by Carrol et al.32 The
modified framework is presented in figure 1. Usually
there is no linear relationship between intervention and
outcomes, but there are a number of effect modifiers
that affect these relationships, such as participants’
response, components, strategies to facilitate the inter-
vention, intervention quality, recruitment and last but
not least, context. These factors influence the imple-
mentation fidelity of the study in terms of adherence of
participants (health managers, providers, patients, users,
etc) to achieve desired outcomes.
Challenges and opportunities for the implementation of
interventions to prevent and control CVD in low-resource
settings in Argentina
The prevalence of CVD and risk factors in Argentina is
high. However, awareness, treatment and control, par-
ticularly for hypercholesterolaemia, are very low. The
Remediar programme is a programme of the National
Ministry of Health that provides free ambulatory drugs
at the point of care to vulnerable people without health
insurance who attend public primary care centres
(PCCs) in Argentina.33 The programme uses the WHO
package for the assessment and management of cardio-
vascular risk in low-resource settings.34
To date, Remediar has provided drugs for the treat-
ment of different cardiovascular risk factors such as anti-
hypertensive and antidiabetic drugs and low-dose
aspirin. Recently, in mid-2014, statins (simvastatin 20mg)
became part of the package of drugs delivered
free-of-charge for patients with high cholesterol and/or
CVD risk, according to CVD risk stratification.
Although the inclusion of statins is crucial to reduce
CVD in vulnerable uninsured subjects with high choles-
terol and moderate-to-high risk CVD, a study that ana-
lysed prescriptions for patients with hypertension at the
point of care in Argentine public clinics reported that
only 57% of patients with hypertension covered by
Remediar were treated. Of those treated, almost 75%
received medication for <4 months/year, and only 12%
for ≥9 months/year.35 Thus, a comprehensive interven-
tion aimed at changing practitioners’ practices and
improving patients’ adherence to drugs is key to reduce
CVD.
Study objectives
The overarching goal of this study is to test whether a
multifaceted educational intervention targeted to physi-
cians and pharmacist assistants at primary care clinics
located in low-income settings improves treatment and
control of hypercholesterolaemia among mostly unin-
sured patients with moderate-to-high cardiovascular risk
in Argentina. The intervention will focus on the public
primary care system through healthcare provider educa-
tion, audit and feedback on the implementation of a
CPG to improve management of statins and global CVD
risk in these patients. The specific aims of this cluster
randomised trial are:
1. to test whether a multifaceted educational interven-
tion programme lowers LDL-C levels and CVD risk in
patients with moderate-to-high cardiovascular risk;
2. to test whether this intervention programme im-
proves physician compliance with clinical practice
guidelines;
3. to test whether this intervention programme im-
proves patient care management and adherence to
medication;
4. to estimate the cost-effectiveness of this comprehen-
sive intervention programme as compared with usual
standard of care.
STUDY DESIGN AND METHODS
Overview of study design
The proposed study tests whether a multifaceted educa-
tional programme targeted at primary care physicians
and pharmacy assistant improves processes and
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outcomes of care in mostly uninsured patients with
hypercholesterolaemia and moderate-to-high cardiovas-
cular risk, in low-resource settings. This cluster RCT is
conducted in 10 public PCCs in Argentina: five clinics
were randomised to receive the intervention programme
and five were randomised to receive usual care (figure
2). It is important to highlight that all clinics, irrespect-
ive of their assignment, will provide statins as prescribed.
The intervention consists in an educational programme
focused on the implementation of a CPG to improve
management of statins in patients with moderate-to-high
CVD risk. The programme includes innovative tools as
mobile phone (mHealth) applications to provide deci-
sion aids to physicians and a web-based platform to send
tailored SMS messages to patients. The study will recruit
35 patients in each clinic for a total of 350 study partici-
pants. Eligible patients will have 12 months of follow-up
after randomisation.
Rationale for using a cluster RCT design
Cluster trials are an adequate design for evaluating
educational outreach and related interventions.
Randomisation by primary care clinic (PCC) is prefer-
able because it avoids the potential contamination that
could occur if randomisation were to be done at individ-
ual level (eg, the cholesterol treatments for patients in
one clinic are more similar to each other than to
patients from another clinic) and also because the effect
of the intervention can be assessed in the natural prac-
tice environment.36
Study population
Ten PCCs from the provinces of Chubut in the
Patagonia (four clinics), Corrientes in the north-east
(four clinics) and La Rioja in the north-west (two
clinics) were included in this trial. Box 1 presents the eli-
gibility criteria for PCCs and patients. Study participants
meeting eligibility criteria were recruited from partici-
pating PCCs to test the intervention in ‘real-world’ clin-
ical settings. Selected PCC staff (physicians, nurses and
pharmacist assistants) worked closely with the study
Figure 1 Conceptual framework for implementation fidelity. Adapted from Carrol C. Implementation Science, 2007.32
Figure 2 Study design.
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team in order to optimise the referral of eligible patients
to study nurses.
Randomisation
The 10 selected PCCs fulfilling the inclusion criteria
were randomised to either the intervention or the
control group: five PCCs to the intervention and five to
the control group. Randomisation was stratified by prov-
ince (Corrientes, Chubut and La Rioja), and it was con-
ducted at the data management centre at the Institute
for Clinical Effectiveness and Health Policy (IECS).
INTERVENTION PROGRAMME
The physician education programme consists of a 2-day
initial intensive training and certification workshop at
IECS. The sessions topics included global cardiovascular
risk assessment and management; diagnosis, treatment
and monitoring of patients with dyslipidaemia, the
chronic care model components and management of
adherence issues in patients with chronic diseases. The
training was followed by EOVs conducted on quarterly
basis (at 3, 6 and 9 months from the outset of the
study), tailored to the needs of clinics’ individual practi-
tioners to identify the barriers to appropriate prescribing
(eg, adequate statin dosage according to CPGs, side
effects of statins, barriers to chronic treatment adher-
ence and so on). EOVs include CPG practical exercises,
prescription-related audits and feedback using selected
charts from patients with high CVD risk and recommen-
dations to improve practice administration/procedures
(eg, support for systematic identification, particularly for
complex patients with low adherence). Finally, an
mHealth application installed in physicians’ smart-
phones used to facilitate evidence-based and guideline-
driven decision aids to improve patient management.
The application was developed using SANA framework
(http://sana.mit.edu), a highly customisable, open-source,
android-based mHealth information system.
Usual care at clinics consists of mostly unscheduled
appointments with a primary care physician on patient’s
demand. All clinics in the network provide ambulatory
drugs free-of-charge at the point of care and most of the
physicians, irrespective of the assignment, have received
previous training in global cardiovascular risk manage-
ment by trainers of the Ministry of Health. In addition,
all clinics were provided with educational flyers and
written material to be displayed at the PCCs, including
charts with the CPG on the use of statins.
In summary, physicians of PCCs randomised to the
intervention group receive a 3-component intervention:
training workshop, EOV’s and an mHealth application
uploaded to their smartphones (figure 3).
In addition to the two main educational components
aimed at primary care physicians, two intervention
support tools are used:
1. A web-based platform tailored to send individualised
SMS messages to encourage patients to adopt healthy
lifestyles, prompts and reminders to engage in
regular visits to their primary care doctors as well as
to improving adherence to statins and other medica-
tion in participating intervention clinics.
2. On-site training to pharmacist assistants during the
first EOV at each intervention clinic. This training
Box 1 Eligibility criteria for study clinics and participants
Eligibility criteria for study clinics (PCCs)
▸ The clinic is affiliated with the Remediar programme.
▸ The clinic is located in a poor urban area according to 2010
census data.
▸ The clinic has ≥800 outpatient adult visits each month (to
ensure recruitment of enough participants).
▸ Physician visits and statins are available free-of-charge to
patients at the point of care.
▸ The minimum distance between PCCs is 10 km (different
catchment area) and they do not share health professionals
(to minimise intervention bias).
▸ Good performance of the PCCs (and their pharmacy) accord-
ing to the reports of Remediar programme.
Eligibility criteria for study participants
Inclusion criteria
Patients aged ≥40 years and <75 years who received primary
care at participating PCCs with at least one of the following
criteria:
▸ Arteriosclerotic cardiovascular disease (ASCVD): defined as
acute coronary syndrome; history of myocardial infarction,
stable or unstable angina, coronary revascularisation, stroke or
transient ischaemic attack presumed to be of atherosclerotic
origin or revascularisation.
▸ High CVD risk according to the WHO charts adapted by the
National MoH (estimated 10-year CVD risk ≥ 20%).37
▸ Low-density lipoprotein cholesterol (LDL-C) level ≥190 mg/dL.





▸ Patients who cannot give informed consent.
▸ History of end-stage chronic kidney disease treated with dialy-
sis, HIV/AIDS, alcohol or drug abuse or active tuberculosis.
Figure 3 Intervention components.
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was focused on counselling to improve medication
adherence among patients initiating statin therapy,
enforced at each patient visit to the clinic to refill
drug prescriptions. Additionally, pharmacist assistants
received educational flyers to be displayed at the
pharmacy.
Treatment algorithm
The algorithm for the use of statins in the treatment of
high cholesterol according to CVD risk was adapted
from the new ACC/AHA Guideline on the Treatment
of Blood Cholesterol to reduce Atherosclerotic
Cardiovascular Risk in Adults5 and the WHO CVD risk
charts.37 Physicians prescribe statins in moderate-to-high
intensity (simvastatin 40 mg) or low-intensity (simvastatin
20 mg) doses according to the CPG (figure 4).
STUDY OUTCOMES
In table 1 is shown which primary and secondary out-
comes will be measured at the end of the trial following
the specific aims mentioned before.
DATA COLLECTION
All questionnaires and measurements are performed by
trained nurses who do not participate in the study in-
tervention. After identifying each potentially eligible
participant, a research physician/nurse explains the
goals and scope of the study, and invites her/him to par-
ticipate and sign a written consent form. The study has
been approved by an independent Internal Review
Board (IRB) at Hospital Italiano of Buenos Aires. A
research nurse administers a questionnaire and records
physical and biochemical measurements at baseline and
at 6 and 12 months during follow-up (table 2).
Study forms and questionnaires include socio-
demographics, history of CVD and risk factors, health
behaviour (eg, smoking, diet and physical activity)
and health services usage patterns and costs. Adherence
to chronic medications are assessed with the Morisky-
Green questionnaire.38
The average value of two blood pressure measure-
ments is obtained at each visit using an automatic device
(OMRON HEM-7200).39 At the clinic visit, anthropomet-
ric measurements are taken on individuals in light cloth-
ing (barefoot) using a standard protocol. Body weight is
measured to the nearest 0.1 kg on a dedicated scale;
body height is measured to the nearest 0.1 cm with a free-
standing stadiometer; body mass index (weight in kilo-
grams divided by the square of height in metres) is cal-
culated as an index for overall obesity and waist
circumference is measured (at the smallest circumference
between the ribs and iliac crest) in centimetres to the
nearest 0.1 cm. We use the Gulick II tape measure (Gays
Figure 4 Treatment algorithm.
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Mills, WI) with a no-stretch, retractable tape and tension-
ing device to minimise measurement error. Each PCC,
irrespective of the assignment, was provided with a
point-of-care testing device, Cholestech LDX and LDX
Capillary Plungers (Alere Cholestech LDX Analyser) to
measure total cholesterol (TC), estimated LDL-C,
HDL-C, triglycerides (TG) and glucose. Point-of-care
testing with this device has been validated in several
studies.40–43 A fasting capillary blood sample is obtained
by finger stick at baseline and during follow-up visits
using a Cholestech LDX analyser.
Follow-up visits are scheduled at 6 and 12 months
(final visit) after the baseline visit. Blood pressure,
anthropometric measures, biochemical measures and
updated information on the use of medications, cigar-
ette smoking, alcohol drinking, diet, physical activity and
costs of treatment are also obtained.
STATISTICAL ANALYSIS
Sample size
The study is designed to have 90% statistical power to
detect a 0.7 mmol/L (27 mg/dL) reduction in LDL-C
level at a significance level of 0.05 using a 2-tailed test,
assuming an intracluster correlation coefficient (ICC) of
0.06.44 45 Power calculations account for cluster design
effect by using the formula developed by Donner and
Klar,46 47 which was implemented in the Power Analysis
and Sample Size (PASS 2008) software (NCSS, Kaysville,
UT). An 85% follow-up rate is assumed. Considering 10
clusters, the estimated sample size for each cluster
(PCC) is 35, accounting for 175 in each group, based on
these assumptions. This sample size ensures adequate
power for testing our secondary outcomes as well.
Analytical planning
The difference in LDL-C levels from baseline to month
12 will be compared between intervention and control
arm. The primary research hypothesis is that this differ-
ence will be greater in the intervention arm compared
with the control arm, showing a greater reduction in
LDL-C level in the intervention arm. We will use
mixed-effects regression analysis with participants and
clinics included as random effects, group, time and
group-by-time interaction as fixed effects.
Intention-to-treat analyses will be conducted. In order
to assess comparability between arms, we will compare
the baseline characteristics of patients (demographics,
clinical variables, lifestyle factors, anthropometrics mea-
sures and laboratory measurements) in the intervention
group versus the control group using one-way ANOVA or
χ2 tests. In addition to this, we will perform subgroup
analyses on primary and secondary outcomes according
to diabetes status and level of CVD risk.
An economic evaluation component based on patient-
level trial data will be supplemented by a model-based
component to extrapolate long-term costs and effects.
The trial-based primary economic evaluation will use
patient-level data collected from the proposed study. We
Table 1 Study outcomes
Specific aim 1 ▸ Net change in LDL-C levels from baseline to month 12 in the intervention group vs
the control group.
Primary outcome
Specific aim 1 ▸ Proportion of patients with moderate and high CVD risk who have reduced their
LDL-C by 30% and 50%, respectively.
Secondary
outcomes
Specific aim 2 ▸ Proportion of patients with high CVD risk who are on statins and are receiving an
appropriate dose according to the CPG.
Specific aim 3 ▸ Net change in 10-year-CVD Framingham Risk Score before and after program
implementation.
▸ Annual number of follow-up visits to the PCC for high CVD risk patients’ level of
treatment adherence evaluated through questionnaire among treated patients.
Specific aim 4 ▸ Incremental cost-effectiveness ratio (ICER) as cost per mg/dL of change in LDL-C,
per treated case, per case receiving an appropriate dose according to the CPG and
per QALY using the Argentina EuroQol EQ-5D.
CPG, clinical practice guidelines; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; PCC; primary care centres.

































*Total cholesterol, estimated low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, triglycerides and glucose.
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will document all resources involved in conducting this
comprehensive intervention programme, as well as all
patient-level costs, in 2017 Argentine Pesos adjusted by
Argentina’s Consumer Price Index and then converted
into international dollars. The primary incremental cost-
effectiveness ratio (ICER) measure will be cost per mg/
dL of change in LDL-C. Secondary measures will be cost
per treated case, per case receiving an appropriate dose
according to the CPG, and per quality-adjusted life-year
(QALY) using the Argentina EuroQol EQ-5D.48
Dissemination
The dissemination plan is designed to translate, commu-
nicate and implement the research findings to inform
health policy, health practice and public opinion. We
will publish the study findings in international and
national peer-review journals and make presentations at
national and international professional meetings. The
results of this implementation research study will be pre-
sented to the Ministry of Health of Argentina for dissem-
ination and scaling-up.
Conclusions and policy implications
Hypercholesterolaemia imposes a heavy burden (with
clinical and economic consequences) on Argentina’s
already overburdened healthcare system. This trial is
designed with an implementation focus and has several
distinctive aspects: there is a high prevalence of undiag-
nosed and uncontrolled population with dyslipidaemia
and high CVD risk in Argentina as well as in most devel-
oping countries.13 14 16 To the best of our knowledge,
this is the first trial in Latin America that tests an educa-
tional intervention to reduce CVD risk targeting primary
care physicians.27 This study is very timely because
statins were recently (2014) added to the national list of
ambulatory drugs provided free-of-charge at Argentine
public primary care clinics, and because there is no CPG
in place in public PCCs aimed specifically at addressing
the management of dyslipidaemia and statins by health
providers. Promoting the adequate use of CPG leads to
the reduction of inappropriate variability in clinical prac-
tice.49 50 In addition, this study is innovative since it will
use a mobile health application as a decision aid to
support physician decision-making and a web-based plat-
form to send tailored SMS messages to patients to
promote behaviour change with respect to improving
adherence to medications, clinical visits and lifestyles
and behaviours.
As the study intervention targets mostly uninsured
populations living in low-income settings, if successful, it
can have an immediate impact in the real world through
the dissemination and scale-up of the intervention pro-
gramme to the entire national public primary care
network in Argentina, thereby reducing health dispar-
ities in CVD risk management and control.
In summary, this study will generate urgently needed
data on effective, practical and sustainable intervention
programmes aimed at preventing and controlling CVD
risk, which can be directly used in other primary care
settings and healthcare systems in LMICs.
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